Mark Altmeyer is an experienced leader in the biotechnology and biopharmaceutical industries, currently serving as Chairperson of the Board at Calluna Pharma and AM-Pharma, alongside board member roles at Aculys Pharma, Alector, Merz Therapeutics, and Novaremed AG. With a background in pioneering innovative therapies for complex neurological and movement disorders, Altmeyer has previously held significant positions including President and CEO of Arvelle Therapeutics and President and Chief Commercial Officer at Axovant Sciences. Altmeyer holds an MBA from Harvard Business School and a BA in Economics from Middlebury College.
This person is not in the org chart
This person is not in any teams
This person is not in any offices